• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Blood Purif . Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment

tetano

Editor, Senior Moderator
Blood Purif


. 2021 Mar 31;1-14.
doi: 10.1159/000513164. Online ahead of print.
Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment


Roghayeh Sheervalilou[SUP] 1 2 [/SUP], Milad Shirvaliloo[SUP] 3 [/SUP], Saman Sargazi[SUP] 2 [/SUP], Soraiya Bahari[SUP] 4 [/SUP], Ramin Saravani[SUP] 2 [/SUP], Jafar Shahraki[SUP] 5 [/SUP], Sakine Shirvalilou[SUP] 6 [/SUP], Omolbanin Shahraki[SUP] 1 2 [/SUP], Ziba Nazarlou[SUP] 7 [/SUP], Zinat Shams[SUP] 8 [/SUP], Habib Ghaznavi[SUP] 1 [/SUP]



Affiliations

Abstract

Since early 2020, COVID-19 has wreaked havoc in many societies around the world. As of the present, the SARS-CoV-2-borne disease is propagating in almost all countries, affecting hundreds of thousands of people in an unprecedented way. As the name suggests, the novel coronavirus, widely known as SARS-CoV-2, is a new emerging human pathogen. A novel disease of relatively unknown origin, COVID-19 does not seem to be amenable to the currently available medicines since there is no specific cure for the disease. In the absence of any vaccine or effective antiviral medication, we have no tools at our disposal, but the method of quarantine, be it domestic or institutional, to hinder any further progression of this outbreak. However, there is a record of physicians in the past who practiced convalescent blood transfusion. To their awe, the method seemed to be useful. It is anticipated that these contemporary methods will outdo any other vaccination process in the time being, as blood transfusion is instead a cost-effective and time-friendly technique. Following a successful trial, this new approach of contemporary nature to a viral disease may serve as an emergency intervention to intercept infectious outbreaks and prevent an impending epidemic/pandemic. In this review, we document the most recent evidence regarding the efficiency of convalescent plasma and serum therapy on SARS, MERS, and particularly COVID-19, while discussing potential advantages and possible risks of such practice.

Keywords: Convalescent blood transfusion; Plasma; SARS-CoV-2/2019-nCoV/COVID-19; Serum (sera); Therapy.
 
Back
Top Bottom